In a monumental step forward for global public health, Indian pharmaceutical companies Dr Reddy’s Laboratories and Hetero Labs have announced they will produce and sell generic versions of a revolutionary HIV prevention drug. It will be available for around $40 per year. Availability is expected from 2027. The drug, lenacapavir, is a long-acting injectable developed by Gilead Sciences. It has…
Category: September 2025
-
America First Health Policy Threatens Global Health Aid
The future of vital United States health aid to South Africa now hangs in the balance. This comes after the Trump administration unveiled a new “America First” global health strategy last week. This move is part of the broader America First health policy initiative announced by the administration. This policy overhaul aims to transition recipient countries towards self-reliance. It does…
-
End of UNAIDS Looms as UN Proposes Agency Closure by 2026
The Joint United Nations Programme on HIV/AIDS (UNAIDS), the principal agency leading the global effort to end the AIDS pandemic, could be dismantled by the end of 2026. This is according to a startling proposal within a new UN document. The move is part of a broader restructuring effort as the international body grapples with a significant funding crisis. The…
-
Upfront Medical Aid Payments a Growing Concern
Upfront medical aid payments cost members of medical aid schemes a staggering R43 billion last year. This is a situation the industry regulator says is causing significant financial hardship and worsening health inequalities. The Council for Medical Schemes (CMS) revealed the figure in its 2023-24 industry report. It highlights a system where members are increasingly shouldering costs that they expect…
-
NCD Prevention: A Smart Investment for Health
The World Health Organisation (WHO) has issued an urgent call to action. It urges countries worldwide to significantly increase their investment in NCD prevention. A new report released by the global health body argues that an additional investment of just $3 per person, per year, could prevent millions of premature deaths. It could also deliver a staggering $1 trillion in…
-
Cancer Court Battle: Patients Deserve Better Treatment
Concerns are mounting over the Gauteng Department of Health’s persistent legal challenges against court orders compelling it to address the province’s devastating cancer treatment backlog. This ongoing cancer court battle highlights significant issues within the healthcare system. Instead of complying with two separate High Court rulings, the department is channelling taxpayer money into an appeal process. This leaves thousands of…
-
HHS Restructuring Plan Blocked by Federal Court
A US Federal Appeals Court has maintained a block on the Trump administration’s ambitious and controversial plan to overhaul the Department of Health and Human Services (HHS). This move would have resulted in 10,000 job losses. Additionally, it would have caused a significant restructuring of key public health agencies. A three-judge panel of the Boston-based 1st US Circuit Court of…
-
NHI Affordability: Key Issues and Legal Perspectives
Multiple groups are challenging the National Health Insurance (NHI) Act. The Western Cape Government is the eighth group to file a lawsuit. A key legal argument in these court cases is NHI affordability. Litigants question whether the state can realistically fund the scheme. This issue forms the foundation of several constitutional challenges against the new law. The outcome of these…
-
Discovery Health Reports Profit Amid Shifting Membership Base
Discovery Health has reported a profit for the recent financial year. This positive result comes despite a slight dip in medical scheme members. The company shows strong financial performance overall. Its strategies are successfully adapting to market changes. This ensures continued profitability and stability. The financial outcome highlights a robust business model. Analysing Membership Trends The Discovery Health Medical Scheme…
-
Ascendis to Delist from the Johannesburg Stock Exchange
Health group Ascendis Health plans a significant change. The company will delist from the Johannesburg Stock Exchange (JSE). It has made a conditional offer to its investors. Ascendis will repurchase shares from them. The market reacted very positively to this news. The company’s stock price surged by 13.4%. This move to delist Ascendis is a key part of its new strategy. The…
-
Mediscor Medicines Review 2024: Key Insights Revealed
The Mediscor Medicines Review 2024 reveals a significant 5.0% increase in medicine expenditure. This marks the most substantial rise in the past three years, presenting a complex challenge for South Africa’s healthcare sector. As a leading pharmaceutical benefits management (PBM) organisation covering over 2.6 million lives, Mediscor’s annual analysis provides a critical barometer for the industry. The 2024 report highlights…